AVIR Q2 2020 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$484M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$8M

Operating Income

-$10M

Net Income

-$10M

EPS (Diluted)

$-0.21

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$209,000

Balance Sheet

Total Assets

$120M

Total Liabilities

$7M

Stockholders' Equity

$113M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$8M	$0	—
Operating Income	-$10M	-$4M	-169.0%
Net Income	-$10M	-$4M	-181.2%